[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Pharmacology](https://durgical.com/en/pharmacology/) › [RANK ligand (RANKL) inhibitors](https://durgical.com/en/pharmacology/classes/rank-ligand-inhibitors/) › Denosumab

# Denosumab

## RANK ligand (RANKL) inhibitors?

RANK ligand (RANKL) inhibitors

## Pregnancy: contraindicated?

Contraindicated in pregnancy: it can harm the fetus. Pregnancy is ruled out first, and effective contraception continues for at least 5 months after the last dose.

An antibody against RANKL, injected under the skin, that strongly lowers bone resorption. Stopping it without a follow-on drug risks vertebral fractures.

Updated Nov 1, 2026

## Quick facts

**Group**
[RANK ligand (RANKL) inhibitors](https://durgical.com/en/pharmacology/classes/rank-ligand-inhibitors/)

**Target**
RANK ligand (RANKL), the cytokine that switches on osteoclasts

**Used for**
Postmenopausal osteoporosis

**Key effects**
Back · Skin reactions · Nausea

**Monitor**
Calcium before each dose and closely · Kidney function

**ATC**
M05BX04

No doses: the clinician sets them by the current guideline.

On this page

- The basics Mechanism of action
- Indications
- Adverse effects
- Pharmacokinetics
- Memory aid

- Clinical What the labels mean

- Safety Contraindications
- Key interactions
- What is monitored
- Administration and safety
- Pregnancy and breastfeeding
- Nursing care

- Study Test yourself

- Connections Connections

## Mechanism of action

Denosumab is a fully human IgG2 monoclonal antibody. It binds RANKL with high affinity and prevents it from activating RANK on osteoclasts and their precursors. Fewer osteoclasts form, the existing ones work less and survive less, and bone resorption falls in all parts of the skeleton. Its effect depends on continued dosing: it is not incorporated into bone, so resorption rises again when it wears off.

- Denosumab binds RANKL in the bone microenvironment
- RANKL can no longer activate RANK on osteoclasts
- Osteoclast formation, function and survival fall
- Resorption drops, density rises; the effect fades if doses stop

## Indications

- Postmenopausal osteoporosis and osteoporosis in men at high fracture risk [Osteoporosis →](https://durgical.com/en/conditions/osteoporosis/)
- Glucocorticoid-induced osteoporosis at high fracture risk [Osteoporotic vertebral compression fracture →](https://durgical.com/en/conditions/osteoporotic-vertebral-compression-fracture/)
- Bone loss from androgen deprivation for prostate cancer [Prostate cancer →](https://durgical.com/en/conditions/prostate-cancer/)
- Bone loss from aromatase inhibitors for breast cancer [Breast cancer →](https://durgical.com/en/conditions/breast-cancer/)
- Prevention of skeletal events in myeloma and bone metastases (oncology product) [Multiple myeloma →](https://durgical.com/en/conditions/multiple-myeloma/)
- Hypercalcaemia of malignancy that does not respond to bisphosphonates (oncology product) [Hypercalcaemia of malignancy →](https://durgical.com/en/conditions/hypercalcaemia-of-malignancy/)

## Adverse effects

### Common

- Back, limb and musculoskeletal pain
- Skin reactions: dermatitis, eczema, rash
- Nausea, diarrhoea or constipation
- Fatigue, headache
- Upper respiratory symptoms

### Serious (rare, important)

- Severe hypocalcaemia, which can be fatal in advanced kidney disease
- Multiple vertebral fractures after stopping or delaying doses
- Serious infections, including skin infections
- Osteonecrosis of the jaw
- Atypical femoral fractures
- Severe hypersensitivity reactions

## Contraindications

- Hypocalcaemia that has not been corrected
- Pregnancy
- Previous systemic hypersensitivity to denosumab
- Not combined with another product that contains denosumab

## Key interactions

**Other drugs that lower calcium (e.g. calcimimetics, other antiresorptives)**
Additive risk of hypocalcaemia

## What is monitored

- Calcium before each dose and closely in the first weeks, especially with kidney disease
- Calcium and vitamin D intake
- Kidney function and mineral bone disorder in advanced kidney disease
- Signs of infection and skin reactions
- Dental health; thigh or groin pain; the date of the next injection

## Administration and safety

- Subcutaneous injection in the upper arm, thigh or abdomen, given by staff
- Calcium and vitamin D are usually prescribed with it
- The osteoporosis and oncology products differ in strength and schedule and are not interchangeable; never two denosumab products together
- Doses are not delayed; stopping is planned with a follow-on antiresorptive

## Pregnancy and breastfeeding

Contraindicated in pregnancy: it can harm the fetus. Pregnancy is ruled out first, and effective contraception continues for at least 5 months after the last dose.

## Nursing care

- Check calcium (and kidney function) before the injection; report a low value
- Teach the signs of low calcium: tingling around the mouth or fingers, cramps, spasms
- Stress keeping the schedule; a missed or late dose raises the risk of vertebral fractures
- Watch for infection (fever, red painful skin) and rash
- Ask about planned dental extractions and teach oral hygiene

## Pharmacokinetics

**Absorption**
Given by subcutaneous injection

**Metabolism**
Broken down like other antibodies, not by the liver or CYP enzymes

**Elimination**
Not cleared by the kidney

**Half-life**
Long, measured in weeks, which allows injections months apart

## Memory aid

DENOsumab: «DE-NO-STOP»: never stop it without a bridge, or the vertebrae pay.

## Test yourself

Think of the answer, then tap the question to see it.

## What is the rebound effect after stopping denosumab?

Bone resorption rises quickly above baseline and multiple vertebral fractures can occur, so a bisphosphonate or other antiresorptive is planned.

## Why can denosumab be used when kidney function is too low for bisphosphonates?

It is an antibody that is not cleared by the kidney, although hypocalcaemia is then more likely and calcium must be watched closely.

## What is checked before each injection of denosumab?

Serum calcium (and vitamin D status); hypocalcaemia must be corrected before the dose.

## How does denosumab differ from a bisphosphonate in how long it acts?

Bisphosphonates are stored in bone and act for years; denosumab is not stored, so its effect lasts only as long as doses continue.

[Add to my cards (4)](https://durgical.app/estudiar/?add=/en/pharmacology/denosumab/)

[More Pharmacology questions →](https://durgical.com/en/practice/?f=pharmacology)

## What the labels mean

**Pregnancy: contraindicated**
Contraindicated in pregnancy: it can harm the fetus. Pregnancy is ruled out first, and effective contraception continues for at least 5 months after the last dose.

## Connections

## Related drugs 3

- [Zoledronic acid](https://durgical.com/en/pharmacology/zoledronic-acid/)
- [Alendronic acid (alendronate)](https://durgical.com/en/pharmacology/alendronic-acid/)
- [Teriparatide](https://durgical.com/en/pharmacology/teriparatide/)

## Related conditions 6

- [Osteoporosis](https://durgical.com/en/conditions/osteoporosis/)
- [Osteoporotic vertebral compression fracture](https://durgical.com/en/conditions/osteoporotic-vertebral-compression-fracture/)
- [Prostate cancer](https://durgical.com/en/conditions/prostate-cancer/)
- [Breast cancer](https://durgical.com/en/conditions/breast-cancer/)
- [Multiple myeloma](https://durgical.com/en/conditions/multiple-myeloma/)
- [Hypercalcaemia of malignancy](https://durgical.com/en/conditions/hypercalcaemia-of-malignancy/)

[← Back to the class: RANK ligand (RANKL) inhibitors](https://durgical.com/en/pharmacology/classes/rank-ligand-inhibitors/)

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: [Denosumab Injection: MedlinePlus Drug Information](https://medlineplus.gov/druginfo/meds/a610023.html) (MedlinePlus (U.S. National Library of Medicine), 2026); [DailyMed - DENOSUMAB-BMWO injection](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a449553-105c-46a1-bb72-849d8f5b81bd) (DailyMed (U.S. National Library of Medicine), 2026); [ATCDDD - ATC/DDD Index](https://atcddd.fhi.no/atc_ddd_index/?code=M05BX04) (WHO Collaborating Centre for Drug Statistics Methodology, 2026).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/pharmacology/denosumab/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/pharmacology/denosumab/